drugset / Trial / NCT01544322
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.
Timeline
- Start
- 2012-05
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ME-344 | Small molecule | 1.2 mg/kg | Intravenous |
| Subject | ME-344 | Small molecule | 2.5 mg/kg | Intravenous |
| Subject | ME-344 | Small molecule | 5 mg/kg | Intravenous |
| Subject | ME-344 | Small molecule | 10 mg/kg | Intravenous |
| Subject | ME-344 | Small molecule | 20 mg/kg | Intravenous |